The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Linkers Having a Crucial Role in Antibody–Drug Conjugates
Open accessAbstract
Antibody–drug conjugates (ADCs) comprised of a desirable monoclonal antibody, an active cytotoxic drug and an appropriate linker are considered to be an innovative therapeutic approach for targeted treatment of various types of tumors and cancers, enhancing the therapeutic parameter of the cytotoxic drug and reducing the possibility of systemic cytotoxicity. An appropriate linker between the antibody and the cytotoxic drug provides a specific bridge, and thus helps the antibody to selectively deliver the cytotoxic drug to tumor cells and accurately releases the cytotoxic drug at tumor sites. In addition to conjugation, the linkers maintain ADCs’ stability during the preparation and storage stages of the ADCs and during the systemic circulation period. The design of linkers for ADCs is a challenge in terms of extracellular stability and intracellular release, and intracellular circumstances, such as the acid environment, the reducing environment and cathepsin, are considered as the catalysts to activate the triggers for initiating the cleavage of ADCs. This review discusses the linkers used in the clinical and marketing stages for ADCs and details the fracture modes of the linkers for the further development of ADCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutathione Metabolism and Its Implications for Health
Wu, G., Lupton, J. R., Turner, N. D., Fang, Y.-Z., & Yang, S. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.3.489 · Cited by 3,842
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Arming antibodies: prospects and challenges for immunoconjugates
Wu, A. M., & Senter, P. D. (2005) · Nature Biotechnology · doi:10.1038/nbt1141 · Cited by 1,052
Shen, B.-Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K. L., Tien, J., Yu, S.-F., Mai, E., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2108 · Cited by 1,008
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
Chari, R. V. J., Miller, M. L., & Widdison, W. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307628 · Cited by 930
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
Chari, R. V. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700108g · Cited by 815
Antibody targeted drugs as cancer therapeutics
Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1957 · Cited by 768
Senter, P. D., & Sievers, E. L. (2012) · Nature Biotechnology · doi:10.1038/nbt.2289 · Cited by 763
Antibody–drug conjugates: targeted drug delivery for cancer
Alley, S. C., Okeley, N. M., & Senter, P. D. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.170 · Cited by 656
Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies
Ducry, L., & Stump, B. (2010) · Bioconjugate Chemistry · doi:10.1021/bc9002019 · Cited by 625
Erickson, H. K., Park, P. U., Widdison, W. C., Kovtun, Y. V., Garrett, L. M., Hoffman, K., Lutz, R. J., Goldmacher, V. S., & Blättler, W. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4489 · Cited by 584
Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates
Trail, P. A., Willner, D., Lasch, S. J., Henderson, A. J., Hofstead, S., Casazza, A. M., Firestone, R. A., Hellström, I., & Hellström, K. E. (1993) · Science · doi:10.1126/science.8327892 · Cited by 556
Dubowchik, G. M., Firestone, R. A., Padilla, L., Willner, D., Hofstead, S. J., Mosure, K., Knipe, J. O., Lasch, S. J., & Trail, P. A. (2002) · Bioconjugate Chemistry · doi:10.1021/bc025536j · Cited by 555
Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., Zabinski, R. F., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0502917 · Cited by 515
Lang, K., Davis, L., Torres-Kolbus, J., Chou, C., Deiters, A., & Chin, J. W. (2012) · Nature Chemistry · doi:10.1038/nchem.1250 · Cited by 487
Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates
Alley, S. C., Benjamin, D. R., Jeffrey, S. C., Okeley, N. M., Meyer, D. L., Sanderson, R. J., & Senter, P. D. (2008) · Bioconjugate Chemistry · doi:10.1021/bc7004329 · Cited by 479
Kovtun, Y. V., Audette, C. A., Ye, Y., Xie, H., Ruberti, M. F., Phinney, S. J., Leece, B. A., Chittenden, T., Blättler, W. A., & Goldmacher, V. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3973 · Cited by 479
Antibody–drug conjugates: current status and future directions
Perez, H. L., Cardarelli, P. M., Deshpande, S., Gangwar, S., Schroeder, G. M., Vite, G. D., & Borzilleri, R. M. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.004 · Cited by 470
Lyon, R. P., Setter, J. R., Bovee, T. D., Doronina, S. O., Hunter, J. H., Anderson, M. E., Balasubramanian, C. L., Duniho, S. M., Leiske, C. I., Li, F., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2968 · Cited by 461
Jain, N., Smith, S. W., Ghone, S., & Tomczuk, B. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1657-7 · Cited by 459
Antibody-Drug Conjugates for Cancer Therapy
Carter, P. J., & Senter, P. D. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318172d704 · Cited by 429
Antibody Conjugate Therapeutics: Challenges and Potential
Teicher, B. A., & Chari, R. V. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1417 · Cited by 427
Kantarjian, H., Thomas, D., Jorgensen, J., Jabbour, E., Kebriaei, P., Rytting, M., York, S., Ravandi, F., Kwari, M., Faderl, S., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70386-2 · Cited by 412
Potent antibody drug conjugates for cancer therapy
Senter, P. D. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.03.023 · Cited by 401
Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry
McCombs, J. R., & Owen, S. C. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9710-8 · Cited by 393
Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Okeley, N. M., Miyamoto, J. B., Zhang, X., Sanderson, R. J., Benjamin, D. R., Sievers, E. L., Senter, P. D., & Alley, S. C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2069 · Cited by 393
Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides
Sun, M. M. C., Beam, K. S., Cerveny, C. G., Hamblett, K. J., Blackmore, R. S., Torgov, M. Y., Handley, F. G. M., Ihle, N. C., Senter, P. D., & Alley, S. C. (2005) · Bioconjugate Chemistry · doi:10.1021/bc050201y · Cited by 370
Katz, J., Janik, J. E., & Younes, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0488 · Cited by 368
Rudnick, S. I., Lou, J., Shaller, C. C., Tang, Y., Klein-Szanto, A. J. P., Weiner, L. M., Marks, J. D., & Adams, G. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2277 · Cited by 365
DiJoseph, J. F., Armellino, D. C., Boghaert, E. R., Khandke, K., Dougher, M. M., Sridharan, L., Kunz, A., Hamann, P. R., Gorovits, B., Udata, C., et al. (2004) · Blood · doi:10.1182/blood-2003-07-2466 · Cited by 361
Addition of the keto functional group to the genetic code of Escherichia coli
Wang, L., Zhang, Z., Brock, A., & Schultz, P. G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0234824100 · Cited by 356
Recent advances in the construction of antibody–drug conjugates
Chudasama, V., Maruani, A., & Caddick, S. (2016) · Nature Chemistry · doi:10.1038/nchem.2415 · Cited by 352
Amiri-Kordestani, L., Blumenthal, G. M., Xu, Q. C., Zhang, L., Tang, S. W., Ha, L., Weinberg, W. C., Chi, B., Candau-Chacon, R., Hughes, P., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0012 · Cited by 351
Site‐Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase
Jeger, S., Zimmermann, K., Blanc, A., Grünberg, J., Honer, M., Hunziker, P., Struthers, H., & Schibli, R. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201004243 · Cited by 344
van der Velden, V. H. J., te Marvelde, J. G., Hoogeveen, P. G., Bernstein, I. D., Houtsmuller, A. B., Berger, M. S., & van Dongen, J. J. M. (2001) · Blood · doi:10.1182/blood.v97.10.3197 · Cited by 338
Iodoacetamide-induced artifact mimics ubiquitination in mass spectrometry
Nielsen, M. L., Vermeulen, M., Bonaldi, T., Cox, J., Moroder, L., & Mann, M. (2008) · Nature Methods · doi:10.1038/nmeth0608-459 · Cited by 286
Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer
Tolcher, A. W., Sugarman, S., Gelmon, K. A., Cohen, R., Saleh, M., Isaacs, C., Young, L., Healey, D., Onetto, N., & Slichenmyer, W. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.478 · Cited by 271
A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy
Maruani, A., Smith, M. E. B., Miranda, E., Chester, K. A., Chudasama, V., & Caddick, S. (2015) · Nature Communications · doi:10.1038/ncomms7645 · Cited by 256
Erickson, H. K., Widdison, W. C., Mayo, M. F., Whiteman, K., Audette, C., Wilhelm, S. D., & Singh, R. (2010) · Bioconjugate Chemistry · doi:10.1021/bc900315y · Cited by 246
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment
McDonagh, C. F., Turcott, E., Westendorf, L., Webster, J. B., Alley, S. C., Kim, K., Andreyka, J., Stone, I., Hamblett, K. J., Francisco, J. A., et al. (2006) · Protein Engineering Design and Selection · doi:10.1093/protein/gzl013 · Cited by 243
CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms
Stein, R., Mattes, M. J., Cardillo, T. M., Hansen, H. J., Chang, C.-H., Burton, J., Govindan, S., & Goldenberg, D. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1167 · Cited by 228
A Novel Endocytic Mechanism of Epidermal Growth Factor Receptor Sequestration and Internalization
Orth, J. D., Krueger, E. W., Weller, S. G., & McNiven, M. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2916 · Cited by 218
Antibody–drug conjugates: Basic concepts, examples and future perspectives
Casi, G., & Neri, D. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.026 · Cited by 210
Saleh, M. N., Sugarman, S., Murray, J., Ostroff, J. B., Healey, D., Jones, D., Daniel, C. R., LeBherz, D., Brewer, H., Onetto, N., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2282 · Cited by 196
Tumey, L. N., Charati, M., He, T., Sousa, E., Ma, D., Han, X., Clark, T., Casavant, J., Loganzo, F., Barletta, F., et al. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500357n · Cited by 192
Dubowchik, G. M., & Firestone, R. A. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00609-x · Cited by 188
Development and Properties of β-Glucuronide Linkers for Monoclonal Antibody−Drug Conjugates
Jeffrey, S. C., Andreyka, J. B., Bernhardt, S. X., Kissler, K. M., Kline, T., Lenox, J. S., Moser, R. F., Nguyen, M. T., Okeley, N. M., Stone, I. J., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0600214 · Cited by 181
Construction of homogeneous antibody–drug conjugates using site-selective protein chemistry
Akkapeddi, P., Azizi, S., Freedy, A. M., Cal, P. M. S. D., Góis, P. M. P., & Bernardes, G. J. L. (2016) · Chemical Science · doi:10.1039/c6sc00170j · Cited by 174
Younes, A., Kim, S., Romaguera, J., Copeland, A., Farial, S. D. C., Kwak, L. W., Fayad, L., Hagemeister, F., Fanale, M., Neelapu, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.4403 · Cited by 170
Sapra, P., Stein, R., Pickett, J., Qu, Z., Govindan, S. V., Cardillo, T. M., Hansen, H. J., Horak, I. D., Griffiths, G. L., & Goldenberg, D. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0204 · Cited by 167
Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
Kim, E. G., & Kim, K. M. (2015) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2015.116 · Cited by 165
Production technologies for monoclonal antibodies and their fragments
Andersen, D. C., & Reilly, D. E. (2004) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2004.08.002 · Cited by 162
Behrens, C. R., Ha, E. H., Chinn, L. L., Bowers, S., Probst, G., Fitch-Bruhns, M., Monteon, J., Valdiosera, A., Bermudez, A., Liao-Chan, S., et al. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00432 · Cited by 162
Law, C., Gordon, K. A., Toki, B. E., Yamane, A. K., Hering, M. A., Cerveny, C. G., Petroziello, J. M., Ryan, M. C., Smith, L. M., Simon, R., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2883 · Cited by 160
Beta-Glucuronidase-Mediated Drug Release
Graaf, M., Boven, E., Scheeren, H., Haisma, H., & Pinedo, H. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023394485 · Cited by 158
Lazar, A. C., Wang, L., Blättler, W. A., Amphlett, G. W., Lambert, J. M., & Zhang, W. (2005) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.1987 · Cited by 155
Drug‐conjugated antibodies for the treatment of cancer
Lambert, J. M. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12044 · Cited by 148
DiJoseph, J. F., Dougher, M. M., Kalyandrug, L. B., Armellino, D. C., Boghaert, E. R., Hamann, P. R., Moran, J. K., & Damle, N. K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1905 · Cited by 140
Laguzza, B. C., Nichols, C. L., Briggs, S., Cullinan, G. J., Johnson, D. A., Starling, J. J., Baker, A. L., Bumol, T. F., & Corvalán, J. R. F. (1989) · Journal of Medicinal Chemistry · doi:10.1021/jm00123a007 · Cited by 134
A Traceless Vascular‐Targeting Antibody–Drug Conjugate for Cancer Therapy
Bernardes, G. J. L., Casi, G., Trüssel, S., Hartmann, I., Schwager, K., Scheuermann, J., & Neri, D. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201106527 · Cited by 133
Bryant, P., Pabst, M., Badescu, G. O., Bird, M., McDowell, W., Jamieson, E., Swierkosz, J., Jurlewicz, K., Tommasi, R., Henseleit, K. D., et al. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00116 · Cited by 127
Nunes, J. P. M., Morais, M., Vassileva, V., Robinson, E., Rajkumar, V. S., Smith, M. E. B., Pedley, R. B., Caddick, S., Baker, J. R., & Chudasama, V. (2015) · Chemical Communications · doi:10.1039/c5cc03557k · Cited by 121
Click Strategies for Single-Molecule Protein Fluorescence
Milles, S., Tyagi, S., Banterle, N., Koehler, C., VanDelinder, V., Plass, T., Neal, A. P., & Lemke, E. A. (2012) · Journal of the American Chemical Society · doi:10.1021/ja210587q · Cited by 120
The next generation of antibody-drug conjugates comes of age.
Beck, A., Haeuw, J., Wurch, T., Goetsch, L., Bailly, C., & Corvaı̈a, N. (2010) · PubMed · Cited by 120
Antibody Conjugates: From Heterogeneous Populations to Defined Reagents
Dennler, P., Fischer, E., & Schibli, R. (2015) · Antibodies · doi:10.3390/antib4030197 · Cited by 116
Oflazoglu, E., Stone, I. J., Gordon, K. A., Wood, C. G., Repasky, E. A., Grewal, I. S., Law, C., & Gerber, H. P. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0916 · Cited by 114
Gemtuzumab Ozogamicin: Time to Resurrect?
Ravandi, F., Estey, E. H., Appelbaum, F. R., Lo‐Coco, F., Schiffer, C. A., Larson, R. A., Burnett, A. K., & Kantarjian, H. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.0132 · Cited by 104
Hamblett, K. J., Kozlosky, C. J., Siu, S., Chang, W., Liu, H., Foltz, I. N., Trueblood, E. S., Meininger, D. P., Arora, T., Twomey, B., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1078 · Cited by 101
Turell, L., Carballal, S., Botti, H., Radí, R., & Álvarez, B. (2009) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2009000400001 · Cited by 97
Progress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery Systems
Jiang, F., Liu, B., Lu, J. G., Li, F., Li, D., Liang, C., Dang, L., Liu, J., He, B., Shaikh, A. B., et al. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161023784 · Cited by 95
Self-citationInvestigational antibody drug conjugates for solid tumors
Sapra, P., Hooper, A. T., O’Donnell, C. J., & Gerber, H. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.582866 · Cited by 92
Next-generation disulfide stapling: reduction and functional re-bridging all in one
Lee, M. T. W., Maruani, A., Baker, J. R., Caddick, S., & Chudasama, V. (2015) · Chemical Science · doi:10.1039/c5sc02666k · Cited by 88
Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs)
Yao, H., Jiang, F., Lü, A., & Zhang, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020194 · Cited by 87
Self-citationConjugation Site Heterogeneity Causes Variable Electrostatic Properties in Fc Conjugates
Boylan, N. J., Zhou, W., Proos, R. J., Tolbert, T. J., Wolfe, J. L., & Laurence, J. S. (2013) · Bioconjugate Chemistry · doi:10.1021/bc4000564 · Cited by 85
Blackwell, K., Miles, D. W., Gianni, L., Krop, I. E., Welslau, M., Baselga, J. M., Pegram, M. D., Oh, D., Dieras, V. C., Olsen, S. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.lba1 · Cited by 84
Antibody drug conjugates — Trojan horses in the war on cancer
Iyer, U. G., & Kadambi, V. J. (2011) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2011.07.005 · Cited by 80
Expanded Utility of the β-Glucuronide Linker: ADCs That Deliver Phenolic Cytotoxic Agents
Jeffrey, S. C., Brabander, J. K. D., Miyamoto, J. B., & Senter, P. D. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100039h · Cited by 73
Takeshita, A., Shinjo, K., Yamakage, N., Ono, T., Hirano, I., Matsui, H., Shigeno, K., Nakamura, S., Tobita, T., Maekawa, M., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07701.x · Cited by 68
Boghaert, E. R., Khandke, K. M., Sridharan, L., Dougher, M. M., DiJoseph, J. F., Kunz, A., Hamann, P. R., Moran, J. K., Chaudhary, I., & Damle, N. K. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0560-2 · Cited by 66
Minor groove binder antibody conjugates employing a water soluble β-glucuronide linker
Jeffrey, S. C., Nguyen, M. T., Moser, R. F., Meyer, D. L., Miyamoto, J. B., & Senter, P. D. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.01.071 · Cited by 59
Wu, H., Nie, Y., Huse, W. D., & Watkins, J. D. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3141 · Cited by 58
Lattanzio, R., Ghasemi, R., Brancati, F., Sorda, R. L., Tinari, N., Perracchio, L., Iacobelli, S., Mottolese, M., Natali, P. G., Piantelli, M., et al. (2014) · Oncogenesis · doi:10.1038/oncsis.2014.32 · Cited by 57
Erratum: Corrigendum: Recent advances in the construction of antibody–drug conjugates
Chudasama, V., Maruani, A., & Caddick, S. (2016) · Nature Chemistry · doi:10.1038/nchem.2467 · Cited by 45
An antibody–cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours
Kelly, R. K., Olson, D. L., Sun, Y., Wen, D., Wortham, K. A., Antognetti, G., Cheung, A. E., Orozco, O. E., Lü, Y., Bailly, V., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.02.023 · Cited by 43
Blackwell, K., Miles, D. W., Gianni, L., Krop, I. E., Welslau, M., Baselga, J. M., Pegram, M. D., Oh, D., Dieras, V. C., Olsen, S. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.18_suppl.lba1 · Cited by 43
Monteiro, I., Madureira, P., de Vasconscelos, A., Pozza, D. H., & de Mello, R. A. (2015) · Pharmacogenomics · doi:10.2217/pgs.14.133 · Cited by 29
Bartlett, N. L., Grove, L. E., Kennedy, D. A., Sievers, E. L., & Forero, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.8062 · Cited by 28
Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies
Robak, T., & Robak, E. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.908184 · Cited by 18
A phase I dose-escalation study of IMGN388 in patients with solid tumors.
Thompson, D. S., Patnaik, A., Bendell, J. C., Papadopoulos, K., Infante, J. R., Mastico, R. A., Johnson, D. H., Qin, A., O'Leary, J. J., & Tolcher, A. W. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3058 · Cited by 16
Effect of HA 14‐1 on Apoptosis‐Regulating Proteins in HeLa Cells
Rehman, K., Tariq, M., Akash, M. S. H., Gillani, Z., & Qazi, M. H. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12245 · Cited by 15
Antibody-drug conjugates as drug carrier systems for bioactive agents
Akash, M. S. H., Rehman, K., Parveen, A., & Ibrahim, M. (2015) · International Journal of Polymeric Materials · doi:10.1080/00914037.2015.1038818 · Cited by 12
Petrylak, D. P., Kantoff, P. W., Rotshteyn, Y., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.7_suppl.158 · Cited by 12
Petrylak, D. P., Kantoff, P. W., Frank, R. C., Shore, N. D., Rotshteyn, Y., Israel, R. J., Olson, W. C., RamaKrishna, T. V., & Morris, S. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.4650 · Cited by 6
Erickson, H. K., Wilhelm, S. D., Widdison, W. C., Leece, B. A., Sun, X., Kovtun, Y., Singh, R., & Chari, R. V. J. (2008) · Cancer Research · Cited by 5
Cited by
Antibody–drug conjugates for cancer
Chau, C. H., Steeg, P. S., & Figg, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31774-x · Cited by 816
Antibody–Drug Conjugates: A Comprehensive Review
Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U., & Zhang, J. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0582 · Cited by 787
Cleavable linkers in antibody–drug conjugates
Bargh, J. D., Isidro-Llobet, A., Parker, J. S., & Spring, D. R. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00676h · Cited by 652
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 605
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Metadata
- Authors
- Lu, J., Jiang, F., Lu, A., & Zhang, G.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2016-04-14
- Volume
- 17
- Issue
- 4
- Pages
- 561
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2337546548
- Cited by
- 285
- References
- 95
- FWCI
- 16.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.